Description
Market Report Coverage – Solid Tumor Testing
Market Segmentation
• Cancer-Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, Brain, Thyroid, Liver, Ovarian and Other
• Application – Clinical and Research
• End User – Academic and Research Institutions, Biopharmaceutical and Biotechnological Companies, Contract Research Organizations, and Other End Users
Regional Segmentation
• North America – U.S., Canada
• Europe – Germany, France, Italy, U.K., Spain, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)
• Latin America – Brazil, Mexico, and Rest-of-the-Latin America
• Rest-of-the-World
Growth Drivers
• Rising Incidence of Cancers
• Decreasing Cost of Sequencing
• Expected Increase in Adoption of Genetic Testing
• Increasing Adoption of Inorganic Growth Strategies
Market Challenges
• Uncertain Reimbursement Policies
• Requirement of High Capital Investment Hindering Expansion
• High Pricing Pressure
Market Opportunities
• Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations
• Increasing Disposable Income in Emerging Companies
• Technological Advancements in the Field of Cancer Genomics
• Mushrooming Direct-to-Consumer Testing Services Market
Key Companies Profiled
Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Beijing Genomics Institute (BGI), QIAGEN N.V., ASURAGEN, INC., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., Invivoscribe, Inc., Inviate Corporation, Opko Health, Laboratory Corporation of American Holdings, OmniSeq, and Guardant Health
Key Questions Answered in this Report:
• What are the major market drivers, challenges, and opportunities in the global solid tumor testing market?
• What is the potential impact of biotechnological advancements in the diagnostic industry among end users such as researchers, pathologists, and laboratory technicians?
• What is the current market demand along with future expected demand for the global solid tumor testing market?
• What are the key development strategies that are implemented by the major players in order to sustain the competitive market?
• How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segments:
o cancer type
o technology
o application
o end user
o region
• Which are the leading players with significant offerings to the global solid tumor testing market?
• What is the expected market dominance for each of these leading players?
• Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global solid tumor testing market?
Market Overview
Our healthcare experts have found the solid tumor testing market to be one of the growing markets, which is predicted to grow at a CAGR of 6.09% during the forecast period, 2020-2030. The market is driven by the need for the development of an advanced solution based on various technologies such as next-generation sequencing, in-situ hybridization, and polymerase chain reaction for cancer research in various applications such as diagnosis, prognosis, and treatment.
The market is favored by the development of high-throughput, rapid, sensitive, and multi-parametric solutions for prognosis, diagnostics, and treatment. The gradual increase in the prevalence of cancer globally has furthered the solid tumor testing market.
Furthermore, several contract research organizations are focusing on the development of solid tumor testing services, which enable to perform an extensive preclinical study at lower operation costs and less turn-around time.
Within the research report, the market is segmented on the basis of cancer type, technology application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of high-resolution multiplex diagnostics providing information on cellular interaction and tissue heterogeneity to understand disease biology and pathology. Due to technologically advanced solutions and intense market penetration, companies such as Quest Diagnostics Incorporated have been a pioneer and a significant competitor in this market.
Other key players in the market are Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Beijing Genomics Institute (BGI), QIAGEN N.V., ASURAGEN, INC., NeoGenomics Laboratories, Inc., Invivoscribe, Inc., Inviate Corporation, Opko Health, Laboratory Corporation of American Holdings, OmniSeq, and Guardant Health.
On the basis of region, North America holds the largest share of the global solid tumor testing market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region.
The global solid tumor testing market utilizes technologies such as next-generation sequencing, in-situ hybridization, immunohistochemistry, polymerase chain reaction, and other technologies for the development of advanced diagnostic tools to cater to a holistic approach toward the treatment of cancer. The rising incidence of cancer and the increasing global burden of the disease has subsequently furthered the growth of the market.
Table of Contents
Executive Summary
1 Product Definition
1.1 Inclusion and Exclusion
2 Market Scope
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Global Solid Tumors Testing Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 Market Overview
4.1 Definition
4.2 Solid Tumor Testing Technologies
4.3 Industry Participants Landscape
4.4 Impact of COVID-19 on Delivery of Care for Cancer Patients
5 Industry Insights
5.1 Regulation of Genetic Tests
5.1.1 FDA Regulation
5.1.2 CMS Regulation
5.2 Legal Requirements and Framework in Europe
5.3 Legal Requirements and Framework in Asia-Pacific
5.3.1 China
5.3.2 Japan
5.4 Reimbursement Scenario
5.4.1 Impact on Laboratory Industry
6 Market Dynamics
6.1 Impact Analysis
6.2 Market Drivers
6.2.1 Rising Incidence of Cancers
6.2.2 Decreasing Cost of Sequencing
6.2.3 Increasing Adoption of Inorganic Growth Strategies in the Market
6.2.4 Expected Increase in Adoption of Genetic Testing
6.3 Market Restraints
6.3.1 Uncertain Reimbursement Policies
6.3.2 Requirement of High Capital Investment Hindering Expansion
6.3.3 High Pricing Pressure
6.4 Market Opportunities
6.4.1 Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations
6.4.2 Technological Advancements in the Field of Cancer Genomics
6.4.3 Mushrooming Direct-to-Consumer (DTC) Testing Services Market
6.4.4 Increasing Disposable Income in Emerging Economies
7 Competitive Landscape
7.1 Key Strategies and Developments
7.1.1 Synergistic Activities
7.1.2 Approvals
7.1.3 Product Launches, Enhancements, and Expansions
7.1.4 Acquisitions and Mergers
7.2 Product Scenario
7.3 Market Share Analysis
7.4 Growth-Share Analysis (Opportunity Mapping)
7.4.1 By Company
7.4.2 By Technology
7.4.3 By Application
7.4.4 By Cancer Type
8 Global Solid Tumor Testing Market (by Technology), $Million, 2019-2030
8.1 Overview
8.2 Next-Generation Sequencing
8.3 In Situ Hybridization
8.4 Polymerase Chain Reaction
8.5 Immunohistochemistry
8.6 Other Technologies
9 Global Solid Tumor Testing Market (by Cancer Type), $Million, 2019-2030
9.1 Overview
9.2 Breast Cancer
9.3 Prostate Cancer
9.4 Colorectal Cancer
9.5 Lung Cancer
9.6 Melanoma
9.7 Endometrial Cancer
9.8 Thyroid Cancer
9.9 Brain Cancer
9.1 Ovarian Cancer
9.11 Liver Cancer
9.12 Other Cancer Types
10 Global Solid Tumor Testing Market, by Application, $Million, 2019-2030
10.1 Overview
10.2 Clinical
10.3 Research
11 Global Solid Tumor Testing Market (by Region), $Million, 2019-2030
11.1 Overview
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 U.K.
11.3.3 France
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 Singapore
11.4.5 Australia
11.4.6 Rest-of-APAC
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest-of-LATAM
11.6 Rest-of-the-World (RoW)
12 Global Solid Tumor Testing Market, by End User, $Million, 2019-2030
12.1 Overview
12.2 Hospitals, Diagnostic Laboratories, and Reference Laboratories
12.3 Pharmaceutical and Biotechnology Companies
12.4 Contract Research Organizations
12.5 Academic Research Institutions
12.6 Other End Users
13 Company Profiles
13.1 Overview
13.2 Abbott Laboratories
13.2.1 Company Overview
13.2.2 Role of Abbott Laboratories in the Global Solid Tumor Testing Market
13.2.3 Financials
13.2.4 Key Insights About Financial Health of the Company
13.2.5 SWOT Analysis
13.3 ARUP Laboratories
13.3.1 Company Overview
13.3.2 Role of ARUP Laboratories in the Global Solid Tumor Testing Market
13.3.3 SWOT Analysis
13.4 ASURAGEN, INC.
13.4.1 Company Overview
13.4.2 Role of ASURAGEN, INC. in the Global Solid Tumor Testing Market
13.4.3 SWOT Analysis
13.5 Bio-Rad Laboratories, Inc.
13.5.1 Company Overview
13.5.2 Role of Bio-Rad Laboratories, Inc. in the Global Solid Tumor Testing Market
13.5.3 Financials
13.5.4 Key Insights About Financial Health of the Company
13.5.5 SWOT Analysis
13.6 Beijing Genomics Institute (BGI) Genomics Co., Ltd
13.6.1 Company Overview
13.6.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the Global Solid Tumor Testing Market
13.6.3 SWOT Analysis
13.7 F. Hoffmann-La Roche Ltd.
13.7.1 Company Overview
13.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Solid Tumor Testing Market
13.7.3 Financials
13.7.4 Key Insights About Financial Health of the Company
13.7.5 SWOT Analysis
13.8 Guardant Health
13.8.1 Company Overview
13.8.2 Role of Guardant Health in the Global Solid Tumor Testing Market
13.8.3 Financials
13.8.4 SWOT Analysis
13.9 Illumina, Inc.
13.9.1 Company Overview
13.9.2 Role of Illumina, Inc. in the Global Solid Tumor Testing Market
13.9.3 Financials
13.9.4 Key Insights About Financial Health of the Company
13.9.5 SWOT Analysis
13.1 Invivoscribe, Inc.
13.10.1 Company Overview
13.10.2 Role of Invivoscribe, Inc. in the Global Solid Tumor Testing Market
13.10.3 SWOT Analysis
13.11 Invitae Corporation
13.11.1 Company Overview
13.11.2 Role of Invitae Corporation, Inc. in the Global Solid Tumor Testing Market
13.11.3 Financials
13.11.4 Key Insights About Financial Health of the Company
13.11.5 SWOT Analysis
13.12 Laboratory Corporation of America Holdings
13.12.1 Company Overview
13.12.2 Role of Laboratory Corporation of America Holdings in the Global Solid Tumor Testing Market
13.12.3 Financials
13.12.4 SWOT Analysis
13.13 NeoGenomics Laboratories, Inc.
13.13.1 Company Overview
13.13.2 Role of NeoGenomics Laboratories, Inc. in the Global Solid Tumor Testing Market
13.13.3 Financials
13.13.4 Key Insights About Financial Health of the Company
13.13.5 SWOT Analysis
13.14 Opko Health
13.14.1 Company Overview
13.14.2 Role of Opko Health, Inc. in the Global Solid Tumor Testing Market
13.14.3 Financials
13.14.4 Key Insights About Financial Health of the Company
13.14.5 SWOT Analysis
13.15 OmniSeq
13.15.1 Company Overview
13.15.2 Role of OmniSeq in the Global Solid Tumor Testing Market
13.15.3 SWOT Analysis
13.16 QIAGEN N.V.
13.16.1 Company Overview
13.16.2 Role of QIAGEN N.V. in the Global Solid Tumor Testing Market
13.16.3 Financials
13.16.4 Key Insights About Financial Health of the Company
13.16.5 SWOT Analysis
13.17 Quest Diagnostics Incorporated
13.17.1 Company Overview
13.17.2 Role of Quest Diagnostics Limited in the Global Solid Tumor Testing Market
13.17.3 Financials
13.17.4 SWOT Analysis
List of Figures
Figure 1: Global Cancer Incidence and Prevalence, Cancer Types, 2020
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Solid Tumor Testing Market
Figure 3: Global Solid Tumor Testing Market (by Technology), $Million, 2020 and 2030
Figure 4: Global Solid Tumor Testing Market (by Cancer Type), $Million, 2020 and 2030
Figure 5: Global Solid Tumor Testing Market (by Application), $Million, 2020 and 2030
Figure 6: Global Solid Tumor Testing Market (by End User), $Million, 2020 and 2030
Figure 2.1: Global Solid Tumor Testing Market Segmentation
Figure 3.1: Global Solid Tumor Testing Market Research Methodology
Figure 6.1: Cancer Cases Projections, 2015-2020
Figure 6.2: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 6.3: Synergistic Activities, 2017-2019
Figure 6.4: SBIR and STTR Grants and Contract Funding, 2008-2018
Figure 6.5: NCI Fiscal Budget Year on Year, 2013-2018
Figure 7.1: Share of Key Strategies and Developments, January 2017-March 2021
Figure 7.2: Synergistic Activities Share (by Company), January 2017-March 2021
Figure 7.3: Approvals Share (by Company), January 2017-March 2021
Figure 7.4: Product Launches, Enhancements and Expansions Share (by Company), January 2017-March 2021
Figure 7.5: Acquisitions and Mergers Share (by Company), January 2017-March 2021
Figure 7.6: Market Share Analysis for the Global Solid Tumor Testing Market, 2020
Figure 7.7: Growth-Share Matrix for Global Solid Tumor Testing Market (by Company), 2020
Figure 7.8: Growth Share Matrix for Global Solid Tumor Testing Market (by Technology), 2020
Figure 7.9: Growth-Share Matrix for Global Solid Tumor Testing Market (by Application), 2020
Figure 7.10: Growth-Share Matrix for Global Solid Tumor Testing Market (by Cancer Type), 2020
Figure 8.1: Global Solid Tumor Testing Market (by Technology), $Million, 2019-2030
Figure 8.2: Global Solid Tumor Testing Market (NGS), $Million, 2019-2030
Figure 8.3: Global Solid Tumor Testing Market (ISH), $Million, 2019-2030
Figure 8.4: Global Solid Tumor Testing Market (for PCR), $Million, 2019-2030
Figure 8.5: Global Solid Tumor Testing Market (IHC), $Million, 2019-2030
Figure 8.6: Global Solid Tumor Testing Market (Other Technologies), $Million, 2019-20230
Figure 9.1: Global Solid Tumor Testing Market (by Cancer Type), $Million, 2019-2030
Figure 9.2: Global Cancer Incidence, 2020
Figure 9.3: Global Solid Tumor Testing Market (Breast Cancer), $Million, 2019-2030
Figure 9.4: Global Cancer Incidence, 2020
Figure 9.5: Global Solid Tumor Testing Market (for Prostate Cancer), $Million, 2019-2030
Figure 9.6: Global Cancer Incidence, 2020
Figure 9.7: Global Solid Tumor Testing Market (Colorectal Cancer), $Million, 2019-2030
Figure 9.8: Global Cancer Incidence, 2020
Figure 9.9: Global Solid Tumor Testing Market (for Lung Cancer), $Million, 2019-2030
Figure 9.10: Global Cancer Incidence, 2020
Figure 9.11: Global Solid Tumor Testing Market (Melanoma), $Million, 2019-2030
Figure 9.12: Global Cancer Incidence, 2020
Figure 9.13: Global Solid Tumor Testing Market (Endometrial Cancer), $Million, 2019-2030
Figure 9.14: Global Cancer Incidence, 2020
Figure 9.15: Global Solid Tumor Testing Market (for Thyroid Cancer), $Million, 2019-2030
Figure 9.16: Global Cancer Incidence, 2020
Figure 9.17: Global Solid Tumor Testing Market (Brain Cancer), $Million, 2019-2030
Figure 9.18: Global Cancer Incidence, 2020
Figure 9.19: Global Solid Tumor Testing Market (Ovarian Cancer), $Million, 2019-2030
Figure 9.20: Global Cancer Incidence, 2020
Figure 9.21: Global Solid Tumor Testing Market (for Liver Cancer), $Million, 2019-2030
Figure 9.22: Global Solid Tumor Testing Market (for Other Cancer Types), $Million, 2019-2030
Figure 10.1: Global Solid Tumor Testing Market (by Application), $Million, 2019-2030
Figure 10.2: Global Solid Tumor Testing Market (by Clinical Applications), $Million, 2019-2030
Figure 10.3: Global Solid Tumor Testing Market (Research Applications), $Million, 2019-2030
Figure 10.4: Global Solid Tumor Testing Market (by Research Applications), $Million, 2019-2030
Figure 11.1: Global Solid Tumor Testing Market (by Region), $Million, 2020 and 2030
Figure 11.2: Global Solid Tumor Testing Market (by Region), $Million, 2019-2030
Figure 11.3: North America Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.4: North America Solid Tumor Testing Market (by Country), $Million, 2019-2030
Figure 11.5: North America: Market Dynamics
Figure 11.6: U.S. Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.7: Canada Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.8: Total Market Size for North America Solid Tumor Testing Market (by Technology), 2020 and 2030
Figure 11.9: Total Market Size for North America Solid Tumor Testing Market (by Cancer), $Million, 2019-2030
Figure 11.10: Europe: Market Dynamics
Figure 11.11: Europe Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.12: Europe Solid Tumor Testing Market (by Country), $Million, 2019-2030
Figure 11.13: Germany Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.14: U.K. Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.15: France Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.16: Italy Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.17: Spain Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.18: Rest-of-Europe (RoE) Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.19: Total Market Size for Europe Solid Tumor Testing Market (by Technology), 2020 and 2030
Figure 11.20: Total Market Size for Europe Solid Tumor Testing Market (by Cancer Type), $Million, 2019-2030
Figure 11.21: Asia-Pacific Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.22: APAC: Market Dynamics
Figure 11.23: Asia-Pacific Solid Tumor Testing Market (by Country), $Million, 2019-2030
Figure 11.24: China Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.25: Japan Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.26: India Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.27: Singapore Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.28: Australia Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.29: Rest-of-APAC Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.30: Total Market Size for Asia-Pacific Solid Tumor Testing Market (by Technology), $Million, 2020 and 2030
Figure 11.31: Total Market Size for Asia Pacific Solid Tumor Testing Market (by Cancer), $Million, 2019-2030
Figure 11.32: Latin America Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.33: Latin America: Market Dynamics
Figure 11.34: Latin America Solid Tumor Testing Market (by Country), $Million, 2019-2030
Figure 11.35: Brazil Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.36: Mexico Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.37: Rest-of-LATAM Solid Tumor Testing Market, $Million, 2019-2030
Figure 11.38: Total Market Size for Latin America Solid Tumor Testing Market (by Technology), $Million, 2020 and 2030
Figure 11.39: Total Market Size for Latin America Solid Tumor Testing Market (by Cancer), $Million, 2019-2030
Figure 11.40: RoW Solid Tumor Testing Market, $Million, 2019-2030
Figure 12.1: Global Solid Tumor Testing Market (by End User), $Million, 2019-2030
Figure 12.2: Global Solid Tumor Testing Market (Hospitals, Diagnostic Laboratories, and Reference Laboratories), $Million, 2019-2030
Figure 12.3: Global Solid Tumor Testing Market (Pharmaceutical and Biotechnology Companies), $Million, 2019-2030
Figure 12.4: Global Solid Tumor Testing Market (Contract Research Organization), $Million, 2019-2030
Figure 12.5: Global Solid Tumor Testing Market (Academic Research Institutions), $Million, 2019-2030
Figure 12.6: Global Solid Tumor Testing Market (Other End Users), $Million, 2019-2030
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: Abbott Laboratories: Portfolio
Figure 13.3: Abbott Laboratories: Overall Financials, 2018-2020
Figure 13.4: Abbott Laboratories: Revenue (by Segment), 2018-2020
Figure 13.5: Abbott Laboratories: Revenue Split for Diagnostics, 2018-2020
Figure 13.6: Abbott Laboratories: Revenue (by Region), 2018-2020
Figure 13.7: Abbott Laboratories: R&D Expenditure, 2018-2020
Figure 13.8: Abbott Laboratories: SWOT Analysis
Figure 13.9: ARUP Laboratories: Portfolio
Figure 13.10: ARUP Laboratories: SWOT Analysis
Figure 13.11: ASURAGEN, INC.: Portfolio
Figure 13.12: ASURAGEN, INC.: SWOT Analysis
Figure 13.13: Bio-Rad Laboratories, Inc.: Portfolio
Figure 13.14: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
Figure 13.15: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 13.16: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
Figure 13.17: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 13.18: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 13.19: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Product Portfolio
Figure 13.20: Beijing Genomics Institute (BGI) Genomics Co., Ltd.: SWOT Analysis
Figure 13.21: F. Hoffmann-La Roche Ltd: Portfolio
Figure 13.22: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
Figure 13.23: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2018-2020
Figure 13.24: F. Hoffmann-La Roche Ltd: Sales (by Region), 2018-2020
Figure 13.25: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020
Figure 13.26: F. Hoffmann-La Roche: SWOT Analysis
Figure 13.27: Guardant Health: Portfolio
Figure 13.28: Guardant Health: Overall Financials, $Million, 2017-2019
Figure 13.29: Guardant Health: Revenue (by Segment), $Million, 2017-2019
Figure 13.30: Guardant Health: Revenue (by Region), $Million, 2017-2019
Figure 13.31: Guardant Health: SWOT Analysis
Figure 13.32: Illumina, Inc.: Portfolio
Figure 13.33: Illumina, Inc.: Overall Financials, 2018-2020
Figure 13.34: Illumina, Inc.: Revenue (by Segment), 2017-2020
Figure 13.35: Illumina, Inc.: Revenue (by Region), 2018-2020
Figure 13.36: Illumina, Inc.: R&D Expenditure, 2018-2020
Figure 13.37: Illumina, Inc.: SWOT Analysis
Figure 13.38: Invivoscribe, Inc.: Portfolio
Figure 13.39: Invivoscribe, Inc.: SWOT Analysis
Figure 13.40: Invitae Corporation: Portfolio
Figure 13.41: Invitae Corporation: Overall Financials, 2018-2020
Figure 13.42: Invitae Corporation: Revenue (by Segment), 2018-2020
Figure 13.43: Invitae Corporation: Revenue (by Geography), 2018-2020
Figure 13.44: Invitae Corporation: R&D Expenditure, 2018-2020
Figure 13.45: Invitae Corporation: SWOT Analysis
Figure 13.46: Laboratory Corporation of America Holdings: Portfolio
Figure 13.47: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2018-2020
Figure 13.48: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
Figure 13.49: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 13.50: NeoGenomics Laboratories, Inc.: Portfolio
Figure 13.51: NeoGenomics Laboratories, Inc.: Overall Financials, 2018-2020
Figure 13.52: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2018-2020
Figure 13.53: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2018-2020
Figure 13.54: NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 13.55: Opko Health: Portfolio
Figure 13.56: Opko Health: Overall Financials, 2018-2020
Figure 13.57: Opko Health: Revenue (by Segment), 2018-2020
Figure 13.58: Opko Health: Revenue (by Region), 2018-2020
Figure 13.59: Opko Health: R&D Expenditure, 2018-2020
Figure 13.60: Opko Health: SWOT Analysis
Figure 13.61: OmniSeq: Portfolio
Figure 13.62: OmniSeq: SWOT Analysis
Figure 13.63: QIAGEN N.V.: Portfolio
Figure 13.64: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 13.65: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 13.66: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 13.67: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 13.68: QIAGEN N.V.: SWOT Analysis
Figure 13.69: Quest Diagnostics Incorporated: Portfolio
Figure 13.70: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 13.71: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
Figure 13.72: Quest Diagnostics Incorporated: SWOT Analysis
List of Tables
Table 4.1: Solid Tumor Testing Technologies for Clinical Laboratories
Table 4.2: Technological Trends in Solid Tumor Testing Market
Table 4.3: Industry Participants Landscape in the Global Solid Tumor Testing Market
Table 5.1: Examples of New CPT Codes Under the CMS
Table 5.2: New Payment Amounts for ADLTs
Table 6.1: Likert Scale
Table 6.2: Impact Analysis of Market Drivers
Table 6.3: Impact Analysis of Market Restraints
Table 7.1: Market Players with Key Product Listing
